Tourmaline Bio, Inc.
TRML
$13.40
-$0.84-5.90%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.26M | 5.11M | 6.24M | 6.14M | 6.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.81M | 24.44M | 21.97M | 17.52M | 14.89M |
| Operating Income | -25.81M | -24.44M | -21.97M | -17.52M | -14.89M |
| Income Before Tax | -22.24M | -20.18M | -17.49M | -13.31M | -12.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.24M | -20.18M | -17.49M | -13.31M | -12.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.24M | -20.18M | -17.49M | -13.31M | -12.90M |
| EBIT | -25.81M | -24.44M | -21.97M | -17.52M | -14.89M |
| EBITDA | -25.80M | -24.43M | -21.96M | -17.51M | -14.88M |
| EPS Basic | -0.86 | -0.78 | -0.68 | -0.55 | -0.81 |
| Normalized Basic EPS | -0.72 | -0.49 | -0.42 | -0.35 | -0.52 |
| EPS Diluted | -0.86 | -0.78 | -0.68 | -0.55 | -0.81 |
| Normalized Diluted EPS | -0.72 | -0.49 | -0.42 | -0.35 | -0.52 |
| Average Basic Shares Outstanding | 25.80M | 25.77M | 25.72M | 24.08M | 16.00M |
| Average Diluted Shares Outstanding | 25.80M | 25.77M | 25.72M | 24.08M | 16.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
